David Haerry

David has been involved with health care professionals’ education projects since 2007 and, in 2015, became Secretary General for the Swiss Academic Foundation on Education in Infectious Diseases (SAFE-ID). He has been Work-Package Co-leader and a member of the Executive Committee for the European Patients’ Academy on Therapeutic Innovation Innovative Medicines Initiative project (EUPATI-IMI).

David was also involved in several European and global research networks and research collaborations, including the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Steering Group and the INSIGHT Trials network. From 2013 to 2016, he co-chaired the Patient and Consumer Working Party at the European Medicines Agency and has served the European AIDS Treatment Group (EATG) in various positions since 2004.

David currently serves on the Scientific Advisory Board for the Ubiquitous Pharmacogenomics Project U-PGx, the ELSI Advisory Group for the Swiss Personalised Health Network SPHN and the Scientific Board of the Swiss HIV Cohort Study SHCS.

He has been involved in HIV and hepatitis C virus (HCV) drug development since 2005 and has specific interests in regulatory affairs, research ethics, personalised medicine, risk communication, pharmacovigilance, observational studies, biomedical prevention and HIV eradication research. He has co-authored a number of peer reviewed publication in infectious diseases, doctor-patient communication and pharmacovigilance